2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. c-Met/HGFR

c-Met/HGFR

c-Met/HGFR

Related Products

PDF 1.01 MB

c-Met (hepatocyte growth factor receptor, HGFR) is a protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. c-Met is a membrane receptor that is essential for embryonic development and wound healing. Hepatocyte growth factor (HGF) is the only known ligand of the c-Met receptor. c-Met is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymalorigin. Upon HGF stimulation, c-Met induces several biological responses that collectively give rise to a program known as invasive growth.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-100946R
    CEP-40783 (Standard)
    		Inhibitor
    CEP-40783 (Standard) is the analytical standard of CEP-40783 (HY-100946). This product is intended for research and analytical applications. CEP-40783 is a potent, selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively.
    CEP-40783 (Standard)
  • HY-13404CR
    Capmatinib dihydrochloride hydrate (Standard)
    		Inhibitor
    Capmatinib (dihydrochloride hydrate) (Standard) is the analytical standard of Capmatinib (dihydrochloride hydrate). This product is intended for research and analytical applications. Capmatinib (INC280; INCB28060) dihydrochloride hydrate is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride hydrate can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride hydrate potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride hydrate is largely metabolized by CYP3A4 and aldehyde oxidase.
    Capmatinib dihydrochloride hydrate (Standard)
  • HY-10261BR
    (E/Z)-Afatinib (Standard)
    		Inhibitor
    (E/Z)-Afatinib (Standard) is the analytical standard of (E/Z)-Afatinib. This product is intended for research and analytical applications. (E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells.
    (E/Z)-Afatinib (Standard)
  • HY-107145AR
    Ningetinib (Standard)
    		Inhibitor
    Ningetinib (Standard) is the analytical standard of Ningetinib (HY-107145A). This product is intended for research and analytical applications. Ningetinib is a potent, orally bioavailable small molecule tyrosine Kinase inhibitor (TKi) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.
    Ningetinib (Standard)
  • HY-13404R
    Capmatinib (Standard)
    		Inhibitor
    Capmatinib (Standard) is the analytical standard of Capmatinib. This product is intended for research and analytical applications. Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase.
    Capmatinib (Standard)
  • HY-100509R
    NPS-1034 (Standard)
    		Inhibitor
    NPS-1034 (Standard) is the analytical standard of NPS-1034 (HY-100509). This product is intended for research and analytical applications. NPS-1034 is a dual inhibitor of AXL and MET with IC50s of 10.3 and 48 nM, respectively.
    NPS-1034 (Standard)
  • HY-50878R
    Crizotinib (Standard)
    		Inhibitor
    Crizotinib (Standard) is the analytical standard of Crizotinib. This product is intended for research and analytical applications. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition.
    Crizotinib (Standard)
  • HY-123225
    LCRF-0004
    		Inhibitor
    LCRF-0004 is a potent inhibitor of RON kinase, with the IC50 value of 10 nM. and a surprising result is also obtained regarding its c-Met inhibitory activity, with the IC50 value of 12 nM. LCRF-0004 plays an important role in cancer research.
    LCRF-0004
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity